SCHEDULE: Vanguard Group Reports Zero Beneficial Ownership in Cytek Biosciences

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cytek Biosciences Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 4 to Schedule 13G regarding its holdings in Cytek Biosciences Inc. Common Stock.
• The filing reports that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of Common Stock of Cytek Biosciences Inc.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Cytek Biosciences Inc., as it primarily reflects an internal reporting change by The Vanguard Group rather than a shift in investment sentiment or a significant transaction.

Management Comments

• The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.

Industry Context

StockSavvy.ai notes that this filing reflects a procedural change in how The Vanguard Group reports its beneficial ownership, rather than a change in its overall investment strategy or a divestment from Cytek Biosciences Inc. This type of internal realignment for reporting purposes is not uncommon among large asset managers.

Stakeholder Impact

• Shareholders of Cytek Biosciences Inc. should understand that this filing represents a change in reporting structure by The Vanguard Group, not necessarily a complete divestment by all Vanguard-managed funds.
• Investment professionals should note that beneficial ownership may now be reported by Vanguard's subsidiaries, requiring a broader view of their holdings.

Key Dates

Keywords

Cytek Biosciences Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Internal Realignment